ALVR
ALVARION LTD ORDINARY SHARESALVR
ALVR
Delisted
ALVR was delisted on the 15th of January, 2014.
Financial journalist opinion
Neutral
Accesswire
13 hours ago
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
Neutral
Accesswire
5 days ago
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
Neutral
Accesswire
1 week ago
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
Neutral
GlobeNewsWire
2 months ago
Kalaris Announces Closing of Merger with AlloVir
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina
Neutral
GlobeNewsWire
3 months ago
Kalaris and AlloVir Announce Stockholder Approval of Merger
Combined company expected to trade on Nasdaq under “KLRS” after closing Combined company expected to trade on Nasdaq under “KLRS” after closing
Charts implemented using Lightweight Charts™